Pathos AI Partners with AstraZeneca to Advance AZD4241 for ER+ Breast Cancer
NEW YORK, Aug. 4, 2026 Pathos AI announced a collaboration and co-exclusive licensing agreement with AstraZeneca to advance AZD4241,...
Inflammation
Advertisement
4Moving Biotech Targets Synovitis with Intra-Articular GLP-1 Therapy
LILLE & PARIS, France, Aug. 4, 2026 4Moving Biotech (4MB) announced the completion of patient enrollment in the Phase...
Novo Nordisk Reports ZEUS Phase 3 Results for Ziltivekimab
BAGSVÆRD, Denmark, July 31, 2026 Novo Nordisk announced headline results from the Phase 3 ZEUS cardiovascular outcomes trial evaluating...
Bambusa Therapeutics Reports Positive Early Phase 1 Results for BBT001 in Atopic Dermatitis
BOSTON, July 27, 2026 Bambusa Therapeutics announced encouraging preliminary proof-of-concept results from its ongoing global Phase 1 clinical trial...
Neumora Therapeutics Announces Positive NMRA-215 Toxicology Findings
WATERTOWN, Mass., July 27, 2026 Neumora Therapeutics announced positive preclinical toxicology results for NMRA-215, its investigational brain-penetrant oral NLRP3...
Advertisements
Arch Biopartners Accelerates IL-32 Chronic Kidney Disease Drug Program
TORONTO, July 17, 2026 Arch Biopartners Inc. has taken a significant step toward advancing its pre-Investigational New Drug (pre-IND)...
Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data
TORONTO, Ontario, July 14, 2026 Cardiol Therapeutics Inc. has announced the publication of its Phase II MAvERIC clinical trial...
Akeso Wins NMPA Approval for Gumokimab in Plaque Psoriasis
HONG KONG, June 11, 2026 Akeso, Inc. announced that China’s National Medical Products Administration (NMPA) has approved gumokimab (AK111,...
Oculis Initiates PREDICT-1 Trial for Licaminlimab in Dry Eye Disease
Oculis, Zug, Switzerland, June 9, 2026 Oculis announced that the first patient has been randomized in the PREDICT-1 registrational...
Edesa Biotech Reports Positive Paridiprubart AKI Data
TORONTO, June 5, 2026 Edesa Biotech, Inc. announced new exploratory analyses demonstrating positive clinical signals for paridiprubart (EB05), its...
Advertisement
